Marstacimab is a medicine used to prevent bleeding in people with hemophilia A or hemophilia B. It works by blocking a protein that slows down blood clotting, so the blood can clot better. It's given as a shot under the skin.
Every report comes from a Lived member, sent anonymously.
Have you tried Hympavzi (Marstacimab) for Hemophilia B?
Marstacimab, sold as Hympavzi, is a weekly injection that prevents bleeding episodes in people with hemophilia A or hemophilia B. Hemophilia is an inherited bleeding disorder in which the blood is low in a clotting protein, factor VIII in hemophilia A or factor IX in hemophilia B, so bleeds into joints and muscles can happen after minor injuries or with no clear cause. Hympavzi is approved for adults and children 6 years and older. It is used for routine prevention, often called prophylaxis, not to stop a bleed that has already started. It can be used whether or not a person has inhibitors, which are antibodies that make standard factor replacement work poorly. Because it does not replace the missing factor, it is one of several non-factor options a hemophilia treatment team may offer as an alternative to regular factor infusions into a vein.
Clotting depends on a balance between proteins that build a clot and proteins that hold clotting in check. One of the brakes is tissue factor pathway inhibitor (TFPI), which slows one of the first steps that starts a clot after an injury. In hemophilia, the missing factor means the clotting process is already weak, so this brake keeps it weaker still. Marstacimab is a monoclonal antibody, a lab-made protein designed to attach to one specific target. It binds to TFPI and blocks it, which lets the body generate more thrombin, the enzyme that turns liquid blood into a clot. This works around the missing factor VIII or IX rather than replacing it, which is why it can work for people with inhibitors. The same effect that reduces bleeding also explains its main safety concern, a higher chance of unwanted clots.
Hympavzi comes as a single-dose prefilled pen or prefilled syringe and is injected under the skin, usually in the belly or the front of the thigh, once a week on the same day at any time of day. Treatment starts with a larger first dose, called a loading dose, then a regular weekly dose a week later. Children 6 to under 12 use a smaller strength than people 12 and older, and the prescriber may raise the weekly dose if bleeding is not controlled well enough. After training, people 12 and older can inject themselves, or a caregiver can give the injection. Before starting, regular factor or bypassing agent prophylaxis is stopped as the care team directs. Bypassing agents are clotting products that work without factor VIII or IX and are used by people with inhibitors. Hympavzi does not treat a bleed in progress, and extra doses should never be used for a breakthrough bleed. Instead, the care team sets out in advance which factor product or bypassing agent to use and at what dose. A missed dose is given as soon as possible. If more than 13 days have passed since the last dose, a new loading dose may be needed, so call the care team for instructions. The pens and syringes are kept in the refrigerator and can be stored once at room temperature for up to 7 days.
The most common side effects are reactions where the shot was given (redness, swelling, hardening, bruising, itching or pain), headache, fever, joint pain, diarrhea, itching and rash. Injection site reactions and fever were more frequent in children than adults in the studies. Blood clots are the most important serious risk. They were uncommon in studies, but they can form in the legs, arms, lungs or head. Stop Hympavzi and get medical help right away for swelling, pain, redness or discoloration in an arm or leg. Call 911 for chest or upper back pain, shortness of breath, coughing up blood, a racing heart or feeling faint, or for numbness in the face, eye pain or swelling, or trouble seeing. Serious allergic reactions are possible. Call 911 for swelling of the face, lips, mouth or tongue, trouble breathing, wheezing, fainting or a pounding heartbeat.
The interaction that matters most is with the clotting products used for breakthrough bleeds. Factor VIII, factor IX and bypassing agents such as recombinant factor VIIa and activated prothrombin complex concentrate (aPCC) can be used alongside Hympavzi, but they add to its clot-promoting effect. The care team will usually recommend the lowest dose that controls the bleed, so it is worth having that written plan before starting. Hympavzi has not been studied in people who have had a blood clot before, and people with coronary artery disease or other blood vessel disease were excluded from the trials. Anyone with clot risk factors should weigh the trade-off carefully with their hematologist. Treatment is usually paused at least 7 days before major surgery, with factor or bypassing agents used to cover the operation. It may also be paused during a serious infection, major injury or other severe illness, when the body's clotting system is already activated. Hympavzi may harm a developing baby. People who could become pregnant need a pregnancy test before starting, should use effective birth control during treatment and for 2 months after the last dose, and should tell the care team right away about a pregnancy. It is not known whether it passes into breast milk. Hympavzi can raise certain clotting blood tests, such as D-dimer, so those results may not reliably show whether a clot is present.
In the main study of people 12 and older, those who had previously treated bleeds only as they happened went from about 40 treated bleeds a year to about 3 on weekly marstacimab. People with inhibitors went from about 20 to under 2. People who had already been on regular factor prophylaxis did at least as well as before, with fewer infusions into a vein. These results come from open-label studies in which each person's bleeding on marstacimab was compared with their own earlier record, not from randomized comparisons with other preventive treatments. The drug builds up over the first couple of months of weekly doses, so breakthrough bleeds are still possible and the plan for treating them stays important. Hympavzi is meant to be used long term, with regular visits to a hemophilia treatment center to review bleeds, joint health and side effects. Some people develop antibodies against the drug, but in studies this did not appear to affect safety or effectiveness over a year. Most study data cover about a year of treatment, so longer-term experience is still building.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Hympavzi (Marstacimab), what you've noticed, or ask the community a question.